Canaccord Genuity Group Cuts ANI Pharmaceuticals (NASDAQ:ANIP) Price Target to $90.00

ANI Pharmaceuticals (NASDAQ:ANIP) had its price objective decreased by research analysts at Canaccord Genuity Group from $91.00 to $90.00 in a report released on Monday,Benzinga reports. The brokerage presently has a “hold” rating on the specialty pharmaceutical company’s stock. Canaccord Genuity Group’s price target suggests a potential upside of 15.02% from the stock’s previous close.

A number of other brokerages have also recently commented on ANIP. Weiss Ratings raised shares of ANI Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Tuesday, June 23rd. Zacks Research cut shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 14th. Wall Street Zen downgraded shares of ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday. Finally, Guggenheim reiterated a “buy” rating and issued a $124.00 price target on shares of ANI Pharmaceuticals in a research report on Friday, July 10th. Five investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $106.67.

ANI Pharmaceuticals Stock Performance

Shares of NASDAQ ANIP opened at $78.25 on Monday. The firm has a fifty day moving average price of $81.02 and a 200-day moving average price of $79.33. The company has a debt-to-equity ratio of 0.99, a current ratio of 2.91 and a quick ratio of 2.41. The stock has a market cap of $1.78 billion, a PE ratio of 16.86 and a beta of 0.44. ANI Pharmaceuticals has a 1 year low of $70.15 and a 1 year high of $99.50.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings data on Friday, August 7th. The specialty pharmaceutical company reported $2.21 EPS for the quarter, beating the consensus estimate of $2.04 by $0.17. ANI Pharmaceuticals had a return on equity of 27.37% and a net margin of 11.07%.The business had revenue of $266.04 million for the quarter, compared to the consensus estimate of $260.13 million. During the same period in the previous year, the business earned $1.80 earnings per share. The business’s revenue was up 25.8% on a year-over-year basis. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Equities analysts anticipate that ANI Pharmaceuticals will post 8.03 earnings per share for the current fiscal year.

Insider Activity at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, Director Thomas Haughey sold 2,000 shares of ANI Pharmaceuticals stock in a transaction on Monday, June 8th. The shares were sold at an average price of $80.88, for a total transaction of $161,760.00. Following the completion of the transaction, the director directly owned 38,878 shares of the company’s stock, valued at $3,144,452.64. The trade was a 4.89% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Stephen P. Carey sold 3,313 shares of the firm’s stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $86.00, for a total transaction of $284,918.00. Following the completion of the sale, the chief financial officer owned 177,543 shares of the company’s stock, valued at $15,268,698. This trade represents a 1.83% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 29,056 shares of company stock valued at $2,367,302 over the last three months. Corporate insiders own 8.10% of the company’s stock.

Hedge Funds Weigh In On ANI Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. raised its position in ANI Pharmaceuticals by 2.2% during the 4th quarter. Vanguard Group Inc. now owns 1,305,068 shares of the specialty pharmaceutical company’s stock valued at $103,022,000 after purchasing an additional 27,598 shares in the last quarter. State Street Corp grew its position in shares of ANI Pharmaceuticals by 2.2% during the 4th quarter. State Street Corp now owns 727,204 shares of the specialty pharmaceutical company’s stock worth $57,405,000 after buying an additional 15,496 shares in the last quarter. UBS Group AG grew its position in shares of ANI Pharmaceuticals by 45.8% during the 3rd quarter. UBS Group AG now owns 589,874 shares of the specialty pharmaceutical company’s stock worth $54,032,000 after buying an additional 185,172 shares in the last quarter. Arrowstreet Capital Limited Partnership increased its stake in shares of ANI Pharmaceuticals by 19.3% during the first quarter. Arrowstreet Capital Limited Partnership now owns 564,360 shares of the specialty pharmaceutical company’s stock valued at $43,399,000 after buying an additional 91,153 shares during the period. Finally, Dimensional Fund Advisors LP increased its stake in shares of ANI Pharmaceuticals by 8.9% during the first quarter. Dimensional Fund Advisors LP now owns 531,190 shares of the specialty pharmaceutical company’s stock valued at $40,843,000 after buying an additional 43,523 shares during the period. 76.05% of the stock is currently owned by institutional investors.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.